Tavalisse™ (fostamatinib) – New drug approval
April 17, 2018 - Rigel Pharmaceuticals announced the FDA approval of Tavalisse (fostamatinib) for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to previous treatment.
Download PDF
